2020
A National Study of Surgically Managed Atypical Pulmonary Carcinoid Tumors
Walters SL, Canavan ME, Salazar MC, Resio BJ, Blasberg JD, Mase V, Boffa DJ. A National Study of Surgically Managed Atypical Pulmonary Carcinoid Tumors. The Annals Of Thoracic Surgery 2020, 112: 921-927. PMID: 33159862, DOI: 10.1016/j.athoracsur.2020.09.029.Peer-Reviewed Original ResearchConceptsAtypical pulmonary carcinoid tumorsPulmonary carcinoid tumorsCarcinoid tumorsCarcinoid patientsAtypical carcinoidStage IMultivariable Cox proportional hazards regressionNon-small cell lung cancerCox proportional hazards regressionAtypical carcinoid patientsTypical pulmonary carcinoidNational Cancer DatabasePredictors of survivalOptimal surgical managementAtypical carcinoid tumorCell lung cancerProportional hazards regressionKaplan-Meier survivalLong-term survivalNodal upstagingSurgical resectionMultivariable analysisSurgical managementHazards regressionLarge tumors
2019
Refining the role of adjuvant chemotherapy in stage IB and IIA NSCLC.
Pathak R, Hoag J, Goldberg S, Monsalve A, Resio B, Boffa D. Refining the role of adjuvant chemotherapy in stage IB and IIA NSCLC. Journal Of Clinical Oncology 2019, 37: 8519-8519. DOI: 10.1200/jco.2019.37.15_suppl.8519.Peer-Reviewed Original ResearchNon-small cell lung cancerNational Cancer Data BaseHigh-risk featuresIIA non-small cell lung cancerAdjuvant chemotherapyStage IBGuideline recommendationsMultivariable Cox proportional hazards regressionBenefit of ACTMulti-agent adjuvant chemotherapyRole of ACSingle-agent adjuvant chemotherapyUse of ACCox proportional hazards regressionStage IB patientsCell lung cancerProportional hazards regressionImmortal time biasNon-academic centersPT2N0 patientsT2a patientsT2b patientsNSCLC patientsSurvival benefitAC patients